How much revenue did Human Metabolome Technologies generate this year?
Human Metabolome Technologies has achieved a revenue of 1.41 B JPY this year.
In 2024, Human Metabolome Technologies's sales reached 1.41 B JPY, a 8.83% difference from the 1.3 B JPY sales recorded in the previous year.
YEAR | REVENUE (undefined JPY) | GROSS MARGIN (%) |
---|---|---|
2026e | 1.48 | 58,13 |
2025e | 1.46 | 59,05 |
2024e | 1.41 | 60,80 |
2023 | 1.3 | 66,17 |
2022 | 1.22 | 68,67 |
2021 | 1.12 | 71,71 |
2020 | 1.12 | 76,60 |
2019 | 0.99 | 67,99 |
2018 | 0.94 | 79,14 |
2017 | 0.91 | 79,75 |
2016 | 0.78 | 73,13 |
2015 | 0.69 | 67,89 |
2014 | 0.61 | 67,50 |
2013 | 0.5 | 59,24 |
2012 | 0.52 | 70,63 |
2011 | 0.57 | 71,28 |
2010 | 0.38 | 67,45 |
2009 | 0.25 | 59,88 |
The sales figures of Human Metabolome Technologies originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Analyzing Human Metabolome Technologies’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Investors often scrutinize Human Metabolome Technologies's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Increases in Human Metabolome Technologies’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Human Metabolome Technologies has achieved a revenue of 1.41 B JPY this year.
The revenue of Human Metabolome Technologies has increased by 8.83% increased compared to the previous year.
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
The revenue of Human Metabolome Technologies is influenced by various factors, including the demand for its products and services, market conditions, and prices.
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
The revenue of Human Metabolome Technologies is an important indicator of financial performance and attractiveness for investors.
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
Over the past 12 months, Human Metabolome Technologies paid a dividend of 10 JPY . This corresponds to a dividend yield of about 1.54 %. For the coming 12 months, Human Metabolome Technologies is expected to pay a dividend of 10 JPY.
The current dividend yield of Human Metabolome Technologies is 1.54 %.
Human Metabolome Technologies pays a quarterly dividend. This is distributed in the months of .
Human Metabolome Technologies paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 10 JPY are expected. This corresponds to a dividend yield of 1.54 %.
Human Metabolome Technologies is assigned to the 'Health' sector.
To receive the latest dividend of Human Metabolome Technologies from 9/1/2024 amounting to 15 JPY, you needed to have the stock in your portfolio before the ex-date on 6/27/2024.
The last dividend was paid out on 9/1/2024.
In the year 2023, Human Metabolome Technologies distributed 0 JPY as dividends.
The dividends of Human Metabolome Technologies are distributed in JPY.
Our stock analysis for Human Metabolome Technologies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Human Metabolome Technologies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.